The National Hemophilia Foundation (NHF) is urging all patients with hemophilia and hepatitis C virus (HCV) to consider enrolling in a clinical trial specifically designed for you. It is also open to patients with HCV and HIV-1. Further, all four HCV genotypes—1, 2, 3 and 4—are included in the study.
This is your opportunity to be a part of a research study for a combination of therapies that are anticipated to cure HCV infection. There are 13 trial sites in the US, from California to New York, that are now recruiting patients.
For a list of participating centers, which are hemophilia treatment centers (HTCs) with either a hemophilia specialist or hepatologist (liver specialist) as the contact for the study, click here.
